C4 Therapeutics (CCCC) Current Assets (2019 - 2026)

C4 Therapeutics' Current Assets history runs 8 years deep, the most recent figure standing at $245.4 million for Q1 2026.

• On a quarterly basis, Current Assets rose 5.52% year-over-year to $245.4 million in Q1 2026; TTM through Mar 2026 was $245.4 million, a 5.52% increase from a year earlier, with the FY2025 full-year figure at $258.1 million, changed 0.13% from the prior year.
• Current Assets fell to $245.4 million in Q1 2026 per CCCC's latest filing, from $258.1 million in the prior quarter.
• Across five years, Current Assets topped out at $325.5 million in Q3 2022 and bottomed at $206.9 million in Q3 2025.
• The 5-year median for Current Assets is $273.2 million (2024), against an average of $266.8 million.
• Across the five-year window, Current Assets slumped 33.34% in 2022 and grew 22.15% in 2024, its largest moves.
• Year by year, Current Assets stood at $287.6 million in 2022, then retreated by 5.69% to $271.2 million in 2023, then fell by 4.95% to $257.8 million in 2024, then grew by 0.13% to $258.1 million in 2025, then slipped by 4.94% to $245.4 million in 2026.
• Per Business Quant, the three latest CCCC Current Assets figures stand at $245.4 million (Q1 2026), $258.1 million (Q4 2025), and $206.9 million (Q3 2025).